Quiz|Articles|June 14, 2025
Dermatology Times Spot Test: June 14, 2025
Author(s)Emma Andrus, Editor
Listen
0:00 / 0:00
Key Takeaways
- Bimekizumab showed sustained efficacy and inflammation control in psoriatic arthritis and axial spondyloarthritis over three years.
- Guselkumab is the only IL-23 inhibitor proven to significantly inhibit joint structural damage progression in active psoriatic arthritis.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Advertisement
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.
This week, we’ll focus on recent developments and updates in psoriatic arthritis from the ongoing European Alliance of Associations for Rheumatology 2025 Congress.
Do you have a set of quiz questions to share? Contact editor Emma Andrus at
Which dual cytokine pathway does bimekizumab (Bimzelx) target in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA)?
In the BE OPTIMAL, BE COMPLETE, and BE VITAL trials, what percentage of patients with active PsA achieved elimination of swollen joints (SJC=0) at 3 years with bimekizumab, regardless of prior treatment exposure?
Which biologic is currently the only IL-23 inhibitor shown in phase 3 trials to significantly inhibit progression of joint structural damage in PsA?
References
- BIMZELX (bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis. News release. UCB. Published June 11, 2024. Accessed June 12, 2025.
https://www.ucb.com/newsroom/press-releases/article/bimzelxrvbimekizumab-three-year-data-at-eular-2025-showed-lasting-efficacy-and-control-of-inflammation-in-psoriatic-arthritis-and-axial-spondyloarthritis - New data show TREMFYA (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis. News release. Johnson & Johnson. June 11, 2025. Accessed June 12, 2025.
https://www.jnj.com/media-center/press-releases/new-data-show-tremfya-guselkumab-is-the-only-il-23-inhibitor-proven-to-significantly-inhibit-progression-of-joint-structural-damage-in-active-psoriatic-arthritis
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
